Biocon Biologics posts strong Q1 growth as North America, Europe deliver

The company’s income grew by 18% annually La2,458 CRORE and EBITDA Similarly increased by 36% La645 Crore in the quarter that ended in June. EBITDA margin rose to 26% in the quarter.

“The growth of this quarter came from North America and Europe both in the advanced markets and primarily in our oncology franchise. Mint In an interview. Tambe said that some of the basic biobenzers in the oncology portfolio such as Fulphila and Ogivri have a market share of more than 25% in these markets.

The company also received the approval of the US Food and Pharmaceutical Administration (FDA) for the first -replaceable fast -effective analogue known to the innovative Novo Nordisk’s Novologist (Insulin Aspart). Tambe said, “Given that there is no competition there, it was very different, only innovative and innovatives showing us and the market,” he said.

The addressable market for insulin Aspart in the USA is a market of $ 1.6 billion for $ 1.2 billion and another fast -acting insulin Lispro (sold as Humalog by Eli Lilly). Tambe said, “It adjusts us very well for future neighborhoods and beyond.

Oncology portfolio is an important focal area for the company. In addition, it will continue to focus on diabetes and autoimmune diseases. The company has five new product launch pipelines in the next 12-18 months, which will increase growth.

Global leadership

North America was the largest market for Biocon Biologics in the last quarter and made up 40% of its income and followed by Europe (35%). Developing markets made up the remaining 25%.

The company bets the growth behind the global biobenzers acquired.

“We had a three -stage strategy for growth: First, it was to protect the value of the acquired being, which was what we did. Last year, we focused on reinforcement; we placed all the building blocks, Tamb Tambe said this year the company plans to accelerate towards growth.

Biocon Biologics acquired the global biobenzer portfolio of US -based Vietris in 2022 to $ 3.3 billion of stocks and cash issues, which has done a completely integrated global biobenzer.

Biocon bets on the biobenzer business to increase growth and turn it into a global leader in the segment. The subsidiary is the largest income driver of BioCon and makes a 61% contribution to total income in 1.Fy26.

Biocon’s executive chairman Kiran Mazumdar-Shaw told investors in his call to investors on Friday after a gain, “We could never be a global biofarmasm company without the purchase of Vietris,” he said.

“This will be a transformative purchase that changes the game that we will make it into real global leaders, Shaw said Shaw, Shaw said.

Successful donations collection

In order to increase his stake in Borcu and BioCon Biologics, Biocon has completed his first self -donation since 2004 public offering in the last quarter. Ascended LaIn June 2025, a qualified corporate placement (QIP) via 4,500 crore.

Funds, Biocon’s subsidiary, Biocon Biologics, will be used to increase the holding of private capital investors, he said.

Biocon Biologics has a net debt of $ 1.1 billion as of June 2025. The funds collected through the QIP will retire the request of Goldman Sachs (NCDs) on request (NCDs), and this will be called with Fiscal Securities and Edelwiss during the company’s management. Siddhaarth Mittal, CEO and General Manager of Biocon, told investors, “… We will start to see that interest costs have fallen.” He said.

Successful Özkaynak Donations Collecting “It is an indication that the market believes in the story, Tam Tambe said. “Secondly, it cleanses the one that is absolutely covered by retiring the whole structured debt… Biocon Limited has a much larger share than before.”

In the fourth quarter of the 25 financial year, the Biocon Board announced that Biocon biology was a strategic committee to evaluate the merger of the parent company. The company also evaluates a public list.